Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 06.10.2025 22 Ann Surg Oncol 2 Anticancer Res 10 BMC Cancer 1 BMJ 3 Br J Cancer 8 Breast Cancer 3 Breast Cancer (Dove Med Press) 10 Breast Cancer Res 2 Breast Cancer Res Treat 1 Cancer 4 Cancer Epidemiol Biomarkers Prev 2 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Cancer 7 Eur J Surg Oncol 1 Eur Radiol 1 Exp Cell Res 5 Int J Radiat Oncol Biol Phys 1 J Biol Chem 2 J Clin Invest 2 J Clin Oncol 1 J Natl Cancer Inst 3 J Nucl Med 1 Lancet Oncol 2 Mod Pathol 11 NPJ Breast Cancer 1 Oncology 7 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. TASHJIAN NL, Hoskin TL, Leon-Ferre RA, Boughey JC, et al
   ASO Visual Abstract: The Association of Clinical Stage at Presentation with Overall Survival in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2025 Sep 29. doi: 10.1245/s10434-025-18358.
   PubMed        
   
   
2. COBB AN, Dong X, Makope A, Cohen L, et al
   Contemporary Nodal Management and Overall Survival of Older Patients with HR-/HER2+ Breast Cancer.
   Ann Surg Oncol. 2025 Sep 29. doi: 10.1245/s10434-025-18417.
   PubMed         Abstract available
   
   
3. HAMID SA, Moses J, Lynch OF, Washington R, et al
   Financial Outlook thRough CAncer STorytelling (FOReCAST): Development of a Novel Video-Based Storytelling Intervention to Mitigate Financial Hardship Among Young Women with Breast Cancer.
   Ann Surg Oncol. 2025 Sep 24. doi: 10.1245/s10434-025-18405.
   PubMed        
   
   
4. PHANG F, Finkelman B, Gooch J, Olzinski-Kunze A, et al
   Real-World Application of Alliance ACOSOG Z11102: How Many Patients Can be Spared Mastectomy?
   Ann Surg Oncol. 2025;32:8271-8279.
   PubMed         Abstract available
   
   
5. CHINN J, Earley M, Dashevsky BZ, Stone K, et al
   Comparison of Two Wireless Localization Technologies for Removal of Non-palpable Breast Lesions: SCOUT((R)) Radar Reflector and Pintuition((R)) Magnetic Seed.
   Ann Surg Oncol. 2025;32:8280-8285.
   PubMed         Abstract available
   
   
6. FERRUCCI M, Milardi F, Passeri D, Miglioranza E, et al
   The Combination of Chest Wall Perforator Flaps and Surgeon-Performed Breast Ultrasound: An Effective Synergy to Expand the Boundaries of Breast-Conserving Surgery.
   Ann Surg Oncol. 2025;32:8538-8551.
   PubMed         Abstract available
   
   
7. PLICHTA JK, Bleicher RJ, Boughey J, Margenthaler JA, et al
   Analysis of the 2024 Breast Surgical Oncology Fellowship Match: Survey of Applicants' and Program Directors' Preferences Regarding In-Person Versus Virtual Interviews.
   Ann Surg Oncol. 2025;32:8514-8522.
   PubMed         Abstract available
   
   
8. SANTORO CN, Hoskin TL, Olson CA, Boughey JC, et al
   Is the Clipped Node Enough? Successful Retrieval and False Negative Rate of the Clipped Node After Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2025;32:8129-8139.
   PubMed         Abstract available
   
   
9. NAASEH A, Tang SX, Lipsey KL, Politi MC, et al
   Feasibility and Efficacy of Decision Aids to Improve Decision-Making for Contralateral Prophylactic Mastectomy: A Systematic Review.
   Ann Surg Oncol. 2025;32:8325-8337.
   PubMed         Abstract available
   
   
10. DICKERSON F, Wiener AA, Breuer C, Schumacher J, et al
    Breast Surgeons' Perspectives of Telehealth Visits for Breast Clinic.
    Ann Surg Oncol. 2025;32:8463-8471.
    PubMed         Abstract available
    
    
11. HUYNH V, Glencer A, Yi M, Wingate E, et al
    Impact of Pathologic Complete Response on Local-Regional Recurrence and Survival in Patients Undergoing Neoadjuvant Systemic Therapy and Breast-Conserving Surgery.
    Ann Surg Oncol. 2025;32:8160-8167.
    PubMed         Abstract available
    
    
12. MILLARD T, Turkheimer LM, Petroni G, Brighton D, et al
    Ninety Days of Preoperative Endocrine Therapy Informs Patient and Physician Preference for Radiation Therapy: Primary Results from the Preoperative Window of Endocrine Therapy to Inform Radiation Therapy Decisions (POWER) Trial.
    Ann Surg Oncol. 2025;32:8169-8179.
    PubMed         Abstract available
    
    
13. MARTIN G, Kensler KH, An A, Gemson E, et al
    Closing the Gap: Disparities in Breast Reconstruction After Mastectomy.
    Ann Surg Oncol. 2025;32:8313-8322.
    PubMed         Abstract available
    
    
14. AMBURN T, Farahani S, Sevilimedu V, Brogi E, et al
    Nipple Discharge and Pathologic Involvement of the Nipple-Areolar Complex: Reconsidering Guidelines for Nipple-Sparing Mastectomy.
    Ann Surg Oncol. 2025;32:8434-8444.
    PubMed         Abstract available
    
    
15. SLOBIN J, Travers G, Perez J, Collins V, et al
    Added Value of Fine-Needle Aspiration (FNA) or Breast Magnetic Resonance Imaging (MRI) as Part of the "Triple Test" to Assess Palpable Abnormalities on a Breast Exam With Negative Imaging Findings.
    Ann Surg Oncol. 2025;32:8378-8385.
    PubMed         Abstract available
    
    
16. CHAN K, Palis BE, Cotler JH, Bleicher RJ, et al
    Association of Surgeon Volume with Adherence to American Society of Breast Surgeons Surgical Quality Measures.
    Ann Surg Oncol. 2025;32:8144-8155.
    PubMed         Abstract available
    
    
17. REAGAN AM, Jones VM, Ibrahim-Zada I, Smith SR, et al
    Characterizing the General Surgery Experience of Future Breast Surgeons: A Multi-institutional Study from the US ROPE Consortium.
    Ann Surg Oncol. 2025;32:8340-8348.
    PubMed         Abstract available
    
    
18. REASON EH, Aiduk MD, Nash AL, McDuff SGR, et al
    Circulating Tumor DNA (ctDNA) is Reliably Detected in Patients with Metastatic Malignant Phyllodes Tumors, a Feasibility Study.
    Ann Surg Oncol. 2025;32:8299-8308.
    PubMed         Abstract available
    
    
19. KAUR M, Dimitroff K, Boughey JC, Esserman LJ, et al
    Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    Ann Surg Oncol. 2025;32:8211-8219.
    PubMed         Abstract available
    
    
20. BHEEMIREDDY S, Leslie SE, Durden JA, Burnet G, et al
    The Use of ChatGPT-4.0 to Simplify Breast Pathology Reports: A Study on Readability and Accuracy.
    Ann Surg Oncol. 2025;32:8400-8408.
    PubMed         Abstract available
    
    
21. SUMMERSIDE M, Istl AC, Rogers CC, Cobb AN, et al
    From Podium to PubMed: Successful Manuscript Publication of Oral Breast Surgery Abstract Presentations at National Meetings from 2017 to 2022.
    Ann Surg Oncol. 2025;32:8184-8191.
    PubMed         Abstract available
    
    
22. AIELLO C, Eum JL, Smilen SH, Pandya D, et al
    Is This the Right Link? How TikTok Views Oncoplastic Breast Surgery.
    Ann Surg Oncol. 2025;32:8369-8373.
    PubMed         Abstract available
    
    

    
    Anticancer Res

23. INOUE S, Miki M, Mizumoto S, Yamamoto M, et al
    Immunohistochemical Evaluation of Tumor Characteristic Retention in Triple-negative Breast Cancer PDOX Models.
    Anticancer Res. 2025;45:4169-4180.
    PubMed         Abstract available
    
    
24. NAGASHIMA Y, Sasaki K, Nohata K, Chiwaki R, et al
    High Expression of PKCzeta and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer.
    Anticancer Res. 2025;45:4357-4372.
    PubMed         Abstract available
    
    

    
    BMC Cancer

25. VARGHESE D, Collins J, Nordstrom B, Miranda M, et al
    Epidemiology and outcomes associated with brain metastases among patients with metastatic breast cancer - a cohort study in US electronic health record data.
    BMC Cancer. 2025;25:1475.
    PubMed         Abstract available
    
    
26. HOSSEINI SS, Askari N, Yaghoobi MM
    Combined anti-tumor effects of metformin and azacitidine in breast cancer cells.
    BMC Cancer. 2025;25:1487.
    PubMed         Abstract available
    
    
27. AFAYA A, Lee H, Kim SY, Park CG, et al
    Multilevel factors associated with clinical breast examination uptake among women in the Northern Region of Ghana: a cross-sectional survey.
    BMC Cancer. 2025;25:1476.
    PubMed         Abstract available
    
    
28. KORANTZIS I, Koumarianou A, Rapti V, Timotheadou E, et al
    Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study).
    BMC Cancer. 2025;25:1473.
    PubMed         Abstract available
    
    
29. AL-TAJ MA
    Sweets consumption and breast cancer risk among women in yemen: a matched case control study.
    BMC Cancer. 2025;25:1495.
    PubMed         Abstract available
    
    
30. WYATT LC, Nguyen CH, LeCroy MN, Foster V, et al
    Prevalence of breast, cervical, and colorectal cancer screenings among select New York City populations.
    BMC Cancer. 2025;25:1469.
    PubMed         Abstract available
    
    
31. CHEN X, Cheng Z, Li Y, Wu X, et al
    Development and validation of a machine learning model to predict delays in seeking medical care among patients with breast cancer in China.
    BMC Cancer. 2025;25:1442.
    PubMed         Abstract available
    
    
32. ZHOU J, Liang B, Su M, Zhang Z, et al
    Long-term exposures to PM(2.5) components increase the breast cancer mortality in the region of Inner Mongolia, China: a retrospective study based on mixture cure model.
    BMC Cancer. 2025;25:1465.
    PubMed         Abstract available
    
    
33. DURRANI S, Al-Ghamdi AA, Al-Bugawi A, Al-Khammash A, et al
    Prognostic factors and survival outcome of brain metastases in breast cancer patients: a retrospective analysis.
    BMC Cancer. 2025;25:1455.
    PubMed         Abstract available
    
    
34. YAHYAPOUR A, Askari N, Yaghoobi MM
    Combination of hydralazine and all-trans retinoic acid targeting breast cancer cells.
    BMC Cancer. 2025;25:1427.
    PubMed         Abstract available
    
    

    
    BMJ

35. MA Z, He W, Zhang Y, Mao X, et al
    First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years: population based cohort study.
    BMJ. 2025;390:e085029.
    PubMed         Abstract available
    
    

    
    Br J Cancer

36. TUMANOVA K, Khorasani M, Nofech-Mozes S, Vitkin A, et al
    Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy.
    Br J Cancer. 2025 Oct 3. doi: 10.1038/s41416-025-03150.
    PubMed         Abstract available
    
    
37. LIU Y, Fan L, Ye F, Zhao Y, et al
    Androgen receptor interacts with c-Myc to regulate macrophage-osteoclast axis and drive bone metastasis in triple negative breast cancer.
    Br J Cancer. 2025 Oct 2. doi: 10.1038/s41416-025-03202.
    PubMed         Abstract available
    
    
38. LIANG H, Benard O, Kumar V, Griffen A, et al
    Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation.
    Br J Cancer. 2025;133:986-1002.
    PubMed         Abstract available
    
    

    
    Breast Cancer

39. YAMADA M, Kubo M, Kaneshiro K, Kai M, et al
    Characterization of gut microbiota dysbiosis in breast cancer patients.
    Breast Cancer. 2025 Oct 2. doi: 10.1007/s12282-025-01782.
    PubMed         Abstract available
    
    
40. ZHAO X, Wang Y, Yang X, Guo H, et al
    TAMs-derived exosomes promote breast cancer progression by regulating the IRF9/IFI6 axis.
    Breast Cancer. 2025 Oct 2. doi: 10.1007/s12282-025-01789.
    PubMed         Abstract available
    
    
41. OGITA M, Sawayanagi S, Jinnouchi H, Yoshimura M, et al
    Postmastectomy radiation therapy for implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese Breast Cancer Society Clinical Practice Guideline.
    Breast Cancer. 2025 Sep 30. doi: 10.1007/s12282-025-01788.
    PubMed         Abstract available
    
    
42. NGUYEN THT, Jeon S, Yoon J, Park B, et al
    Global mapping of artificial intelligence applications in breast cancer from 1988-2024: a machine learning approach.
    Breast Cancer. 2025 Sep 29. doi: 10.1007/s12282-025-01783.
    PubMed         Abstract available
    
    
43. CELIK O, Ozgul H, Cakir RC, Lale A, et al
    Comparative analysis of level II oncoplastic surgery and conventional breast-conserving surgery in breast cancer with a ductal carcinoma in situ component.
    Breast Cancer. 2025 Sep 28. doi: 10.1007/s12282-025-01786.
    PubMed         Abstract available
    
    
44. REZAEI MH, Meymandi MS, Moslemizadeh A, Madadizadeh E, et al
    The therapeutic potential of high-intensity interval training in a breast cancer model: focus on the Hippo signaling pathway.
    Breast Cancer. 2025 Sep 27. doi: 10.1007/s12282-025-01773.
    PubMed         Abstract available
    
    
45. WATANABE A, Kitano S, Kato C, Tsunashima R, et al
    Pathological homogeneity and utility in the genetic diagnosis of paired mirror samples from breast cancer 10G-vacuum-assisted biopsies using a novel longitudinal dividing device.
    Breast Cancer. 2025 Sep 25. doi: 10.1007/s12282-025-01778.
    PubMed         Abstract available
    
    
46. OGITA M, Sawayanagi S, Jinnouchi H, Yoshimura M, et al
    Timing of postmastectomy radiation therapy in two-stage expander/implant-based breast reconstruction: a systematic review and meta-analysis for the 2022 Japanese breast cancer society clinical practice guideline.
    Breast Cancer. 2025 Sep 25. doi: 10.1007/s12282-025-01785.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

47. YAN Y, Jin Y, Lin M, Zeng C, et al
    Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China.
    Breast Cancer (Dove Med Press). 2025;17:863-873.
    PubMed         Abstract available
    
    
48. LU Y, Ren L, Yang M, Liu J, et al
    Clinical Management of Circulating Tumor DNA in Breast Cancer: Detection, Prediction, and Monitoring.
    Breast Cancer (Dove Med Press). 2025;17:851-861.
    PubMed         Abstract available
    
    
49. LONNING PE, Nikolaienko O, Knappskog S
    Triple-Negative Breast Cancer on the Rise or...? [Letter].
    Breast Cancer (Dove Med Press). 2025;17:875-876.
    PubMed        
    
    

    
    Breast Cancer Res

50. FONTANA A, Barbano R, Pasculli B, Mazza T, et al
    Development of a microRNA-based prognostic model for accurate prediction of distant metastasis in breast cancer patients.
    Breast Cancer Res. 2025;27:170.
    PubMed         Abstract available
    
    
51. MAHMOUD MA, Winham SJ, Scott CG, Ehsan S, et al
    Interplay of BMI and volumetric breast density measures and breast cancer risk for black and white women.
    Breast Cancer Res. 2025;27:167.
    PubMed         Abstract available
    
    
52. FANUCCI K, Yeh ED, Shi R, Qin L, et al
    Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
    Breast Cancer Res. 2025;27:171.
    PubMed         Abstract available
    
    
53. KOYAMA Y, Muguruma M, Horimoto Y, Narui K, et al
    Hsa-miR-155-5p expression in primary breast tissue may have the potential for prediction of breast cancer brain recurrence: results from the multi-institutional exploratory cohort study.
    Breast Cancer Res. 2025;27:169.
    PubMed         Abstract available
    
    
54. VERMA D, Nandi D, Parida S, Saxena A, et al
    An enteropathogenic microbial toxin modulates the breast cancer epigenome resulting in concurrent silencing of tumor suppressor genes.
    Breast Cancer Res. 2025;27:163.
    PubMed         Abstract available
    
    
55. SUNG H, Jiang C, Jatoi I, Jemal A, et al
    Trends in breast cancer death rates from ductal carcinoma in situ versus invasive cancer in the United States.
    Breast Cancer Res. 2025;27:164.
    PubMed         Abstract available
    
    
56. WONG C, Yang Q, Liang Y, Wei Z, et al
    AI-driven MRI biomarker for triple-class HER2 expression classification in breast cancer: a large-scale multicenter study.
    Breast Cancer Res. 2025;27:166.
    PubMed         Abstract available
    
    
57. YANG Z, Lian X, Luo Y, Ye Q, et al
    Glutamine synthetase shields triple-negative breast cancer cells from ferroptosis in metastasis triggered by glutamine deprivation.
    Breast Cancer Res. 2025;27:165.
    PubMed         Abstract available
    
    
58. OGONY JW, Pacheco-Spann LM, Arnold A, Cabezas JV, et al
    A STAT1-GBP1 axis modulates epithelial proliferation in postpartum breast tissue by repressing CDKI expression.
    Breast Cancer Res. 2025;27:162.
    PubMed         Abstract available
    
    
59. WANG M, Mo S, Li G, Zheng J, et al
    Deep learning and radiomics integration of photoacoustic/ultrasound imaging for non-invasive prediction of luminal and non-luminal breast cancer subtypes.
    Breast Cancer Res. 2025;27:161.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

60. PIENIAZEK M, Polakiewicz-Gilowska A, Las-Jankowska M, Wronowicz J, et al
    Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis.
    Breast Cancer Res Treat. 2025 Sep 27. doi: 10.1007/s10549-025-07825.
    PubMed         Abstract available
    
    
61. HUANG Z, Liu Y, Li S, Li Y, et al
    Correction: IHC4 and COMBINE scores for enhanced prognostic stratification in HR+/HER2- breast cancer patients after neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2025 Sep 25. doi: 10.1007/s10549-025-07824.
    PubMed        
    
    

    
    Cancer

62. NIERENGARTEN MB
    Omission of postoperative radiotherapy considered in older patients with breast cancer.
    Cancer. 2025;131:e70077.
    PubMed        
    
    

    
    Cancer Epidemiol Biomarkers Prev

63. PINHEIRO LC, Reeder-Hayes KE
    The Honest Broker: Reimagining the Roles of Health Services Research, Community Partnership, and Policymaking to Address Structural Determinants of Cancer Outcomes.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1683-1685.
    PubMed         Abstract available
    
    
64. TIMBRES J, Kohut K, Mavaddat N, Easton DF, et al
    Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    
65. AL HASAN SM, Toriola AT
    Prevalence and Determinants of Mammography Use among Women Aged 40 to 49 Years in the United States.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1759-1770.
    PubMed         Abstract available
    
    
66. HOLOWATYJ AN, Liu L, Munro HM, Perkins-Smith JJ, et al
    Income, Race, and Survival among Low-Income Black and White Americans with Lung, Breast, Prostate, or Colorectal Cancer.
    Cancer Epidemiol Biomarkers Prev. 2025;34:1749-1758.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

67. ESMAEILIZADEH N, Maleki-Kakelar H, Sharifi R, Valilou S, et al
    Effects of Different Glucose Concentrations and Hypoxia and its Impact on the Expression of Sox2 and CAIX in Breast Cancer: In Vitro And Silico Analysis.
    Clin Breast Cancer. 2025 Sep 3:S1526-8209(25)00249.
    PubMed         Abstract available
    
    
68. QIAN D
    Unmeasured Social Determinants and Residual Survival Differences in Early Triple-Negative Breast Cancer: A Cautionary Note to Gaba et al.
    Clin Breast Cancer. 2025 Sep 6:S1526-8209(25)00252.
    PubMed        
    
    

    
    Clin Cancer Res

69. MURDTER TE, Schroth W, Goetz MP, Tremmel R, et al
    Supplementation of Tamoxifen with low-dose Endoxifen in breast cancer patients with impaired tamoxifen metabolism (TAMENDOX): a randomized controlled phase 1/2 trial.
    Clin Cancer Res. 2025 Oct 2. doi: 10.1158/1078-0432.CCR-25-2103.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

70. ZHANG S, Sun T, Wang X, Yan M, et al
    Efficacy and safety of MRG002 monotherapy in treating patients with locally advanced or metastatic breast cancer with low HER2 expression: A multi-center, non-randomized, open-label phase II clinical trial.
    Eur J Cancer. 2025;230:115794.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

71. CREWE E, Tyrer F, Deanfield J, de Belder M, et al
    Geographic variation in surgery rates among older patients with early (ER positive HER2 negative) breast cancer: Influence of cardiovascular disease and comorbidities: A national registry dataset analysis.
    Eur J Surg Oncol. 2025;51:110432.
    PubMed         Abstract available
    
    
72. LEE CE, Nam SJ, Kim SW, Yu J, et al
    Re-evaluating the necessity of removing residual calcifications detected after surgery in HR-/HER2+ breast cancer with pathologic complete response.
    Eur J Surg Oncol. 2025;51:110476.
    PubMed         Abstract available
    
    
73. SCHULTEK G, Gerber B, Hartmann S, Reimer T, et al
    Clinical implications of clip migration after stereotactic-assisted vacuum-assisted breast biopsies.
    Eur J Surg Oncol. 2025;51:110393.
    PubMed         Abstract available
    
    
74. MOLSKA M, Wojciech M, Pieszko K, Ciesla S, et al
    Randomized controlled trial comparing single-use negative-pressure wound therapy (sNPWT) with standard dressings during tissue expander-to-implant exchanges. Assessment of risk factors for impaired wound healing and clinical indications for sNPWT.
    Eur J Surg Oncol. 2025;51:110355.
    PubMed         Abstract available
    
    
75. KAIDAR-PERSON O, Poortmans P, Offersen BV, Meattini I, et al
    Optimising mastectomy with a focus on skin and nipple-sparing approaches: a multidisciplinary point of view.
    Eur J Surg Oncol. 2025;51:110310.
    PubMed         Abstract available
    
    
76. HAMANN M, Bensmann E, Andrulat A, Festl J, et al
    Real-world quality of life outcomes after prepectoral implant-based breast reconstruction with or without titanium-coated mesh (TiLOOP(R) Bra Pocket): A prospective cohort study.
    Eur J Surg Oncol. 2025;51:110311.
    PubMed         Abstract available
    
    
77. SANCHEZ AM, De Lauretis F, Bucaro A, Pirrottina CV, et al
    Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM * study group. ( *the breast European association for mesenchymal tumors).
    Eur J Surg Oncol. 2025;51:110265.
    PubMed         Abstract available
    
    

    
    Eur Radiol

78. LI Y, Wang J, Guo J, Yue C, et al
    Longitudinal wash-in slope changes on dynamic contrast enhancement MRI for predicting response to neoadjuvant chemotherapy in breast cancer.
    Eur Radiol. 2025 Oct 3. doi: 10.1007/s00330-025-12042.
    PubMed         Abstract available
    
    

    
    Exp Cell Res

79. WU G, Yao W, Cheng L, Wang X, et al
    SIRT1 rescues autophagic flux via PI3K/AKT/mTOR inactivation to suppress DOX-induced senescence in MCF-7 cells.
    Exp Cell Res. 2025;452:114754.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

80. TELES MS, Lapen K, Huang J, Mao JJ, et al
    Assessing the Implementation of Electronic Patient-Reported Outcomes (ePRO) to Reduce Follow-up Visits for Patients Undergoing Radiation Therapy for Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 28:S0360-3016(25)06289.
    PubMed         Abstract available
    
    
81. TERRY AR, Boe L, Pawloski KR, O'Brien DR, et al
    Partial Breast Irradiation for High Molecular Risk Early-Stage Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Jun 12:S0360-3016(25)00486.
    PubMed         Abstract available
    
    
82. STECKLEIN SR, Salgado R, White JR, Kimler BF, et al
    Analysis of the Radiosensitivity Index (RSI) in Paired Pre- and Post-Neoadjuvant Therapy Triple-Negative Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2025 Sep 25:S0360-3016(25)06302.
    PubMed         Abstract available
    
    
83. WADASADAWALA T, Syeda N, Kenekar S, Krishnamurthy R, et al
    Cumulative Risk of Cosmetic Worsening Following Ultrahypofractionated Whole Breast Radiation Therapy With Simultaneous Integrated Boost: The Largest Real-World Data.
    Int J Radiat Oncol Biol Phys. 2025;123:732-741.
    PubMed         Abstract available
    
    
84. LOAP P, Loirat D, Stern MH, Pierga JY, et al
    Safety and Potential Radiosensitizing Effect of Olaparib in Combination With Breast Radiation Therapy for Patients With Triple-Negative Breast Cancer With Residual Disease: Long-Term Results From the RADIOPARP Phase 1 Trial.
    Int J Radiat Oncol Biol Phys. 2025;123:726-731.
    PubMed         Abstract available
    
    

    
    J Biol Chem

85. YU H, Zhou Q, Chen Y, Zhong C, et al
    Neddylation inhibitor MLN4924 enhances H3K18 lactylation via binding to LDH and downregulates ITGB4 to block metastasis.
    J Biol Chem. 2025;301:110575.
    PubMed         Abstract available
    
    

    
    J Clin Invest

86. WANG S, Liang K, Hu Q, Li P, et al
    Expression of Concern for JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.
    J Clin Invest. 2025;135:e200302.
    PubMed        
    
    
87. KUMARI N, Wright SC, Witham CM, Monserrat L, et al
    USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.
    J Clin Invest. 2025 Sep 23:e180927. doi: 10.1172/JCI180927.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

88. DICKERSON JC, Caswell-Jin JL, Riaz F, Goldhaber-Fiebert JD, et al
    Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.
    J Clin Oncol. 2025 Sep 24:JCO2501879. doi: 10.1200/JCO-25-01879.
    PubMed        
    
    
89. WU J, Ma D, Xing Z
    Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.
    J Clin Oncol. 2025 Sep 24:JCO2501656. doi: 10.1200/JCO-25-01656.
    PubMed        
    
    

    
    J Natl Cancer Inst

90. SYMONDS LK, Davidson NE
    RecOVARY? Using anti-Mullerian hormone to predict ovarian function after anti-HER2 therapy for early breast cancer.
    J Natl Cancer Inst. 2025 Sep 26:djaf247. doi: 10.1093.
    PubMed        
    
    

    
    J Nucl Med

91. MCNALLY LR, Claros-Sorto JC, Bynum RC, Grizzle WE, et al
    Assessment of Breast Tumors Using Multispectral Optoacoustic Tomography in a Surgical Setting.
    J Nucl Med. 2025;66:1597-1604.
    PubMed         Abstract available
    
    
92. RYU J, Han S, Yoo TR, Lee SB, et al
    Diagnostic Performance of (18)F-Fluoroestradiol PET/CT for Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma: A Prospective Feasibility Study.
    J Nucl Med. 2025 Aug 14:jnumed.125.269573. doi: 10.2967/jnumed.125.269573.
    PubMed         Abstract available
    
    
93. KUJAWSKI M, Aniogo E, Wong P, Hui S, et al
    Combination Image-Guided and Antibody-Targeted alpha-Therapy Before Targeted Immunotherapy for Treatment of Solid Tumors.
    J Nucl Med. 2025;66:1605-1611.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

94. BIRRELL SN
    Synthetic progestin use and young-onset breast cancer.
    Lancet Oncol. 2025;26:e516.
    PubMed        
    
    

    
    Mod Pathol

95. KHOURY T, Zhan H, Huang X, Ghasemi F, et al
    Predicting the Probability of Residual Axillary Nodal Metastases in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    Mod Pathol. 2025 Oct 1:100902. doi: 10.1016/j.modpat.2025.100902.
    PubMed         Abstract available
    
    
96. MORRAR D, Brogi E, Schwartz CJ, Pareja F, et al
    HER2-ultralow Breast Cancer: Incidence, Clinicopathologic Features and Need for Refined Scoring System.
    Mod Pathol. 2025 Sep 29:100901. doi: 10.1016/j.modpat.2025.100901.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

97. COLLISTER JA, Smith-Byrne K, Atkins J, Reeves G, et al
    Meta-analysis of exome-wide gene burden analysis of breast cancer susceptibility genes.
    NPJ Breast Cancer. 2025;11:111.
    PubMed         Abstract available
    
    
98. ABUHADRA N, Pareja F, White C, Chen Y, et al
    Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer.
    NPJ Breast Cancer. 2025;11:110.
    PubMed         Abstract available
    
    
99. CORTES J, Lipatov O, Im SA, Goncalves A, et al
    Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy.
    NPJ Breast Cancer. 2025;11:109.
    PubMed         Abstract available
    
    
100. TSAI CH, Huang WL, Su YW, Lee F, et al
     Longitudinal changes in gut microbiota composition during endocrine therapy in hormone receptor-positive breast cancer patients.
     NPJ Breast Cancer. 2025;11:107.
     PubMed         Abstract available
     
     
101. YAO X, Shen X, Fan Y, Wang H, et al
     TRIM39-mediated deubiquitination upregulates RNF168 to evade autophagy-ferroptosis in triple-negative breast cancer.
     NPJ Breast Cancer. 2025;11:108.
     PubMed         Abstract available
     
     
102. MULDER CV, Yang X, Jee YH, Scott CG, et al
     Evaluating mammographic density's contribution to improve a breast cancer risk model with questionnaire-based and polygenic factors.
     NPJ Breast Cancer. 2025;11:106.
     PubMed         Abstract available
     
     
103. TAI MC, Dennis J, Park SK, Kim SW, et al
     Polygenic risk score for breast cancer risk prediction in Asian BRCA1 and BRCA2 pathogenic variants carriers.
     NPJ Breast Cancer. 2025;11:105.
     PubMed         Abstract available
     
     
104. VALLE I, Grinda T, Antonuzzo L, Pistilli B, et al
     Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives.
     NPJ Breast Cancer. 2025;11:102.
     PubMed         Abstract available
     
     
105. BALKO JM, Licata L, Wang XQ, Dugo M, et al
     Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer.
     NPJ Breast Cancer. 2025;11:103.
     PubMed         Abstract available
     
     
106. BRUCE K, Kerin M, Richard V
     The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer.
     NPJ Breast Cancer. 2025;11:104.
     PubMed         Abstract available
     
     
107. DE CREM AS, Tummers P, Depypere H, Braems G, et al
     Breast cancer Intraoperative Margin Assessment using specimen PET-CT (BIMAP).
     NPJ Breast Cancer. 2025;11:101.
     PubMed         Abstract available
     
     

     
     Oncology

108. GO M, Kimura M, Yamada S, Kamei K, et al
     Safety and Treatment Continuity of Switching Between CDK4/6 Inhibitors for Metastatic Breast Cancer Due to Adverse Events: An Exploratory Single-Center Study in Japan.
     Oncology. 2025 Oct 3:1-17. doi: 10.1159/000548801.
     PubMed         Abstract available
     
     

     
     PLoS One

109. ZIEGLER RODRIGUEZ G, De La Cruz Ku G, Hickey A, Roberts S, et al
     Special histological subtypes of breast cancer in a Hispanic Latino population.
     PLoS One. 2025;20:e0333139.
     PubMed         Abstract available
     
     
110. ZHANG F, Zhou C, Yang Y, Li J, et al
     Clinicopathological and prognostic exploratory study of primary metaplastic squamous cell carcinoma of the breast.
     PLoS One. 2025;20:e0333347.
     PubMed         Abstract available
     
     
111. MADARIAGA B, Mondschein S, Torres S
     Inequities in breast cancer outcomes in Chile: An analysis of case fatality ratios and survival rates (2007-2018).
     PLoS One. 2025;20:e0325252.
     PubMed         Abstract available
     
     
112. MITCHELL HJ, McShane CM, Hawkins ST, Lohfeld L, et al
     Impact of COVID-19 on breast cancer patients and services in a UK region: Protocol for a mixed methods study.
     PLoS One. 2025;20:e0333288.
     PubMed         Abstract available
     
     
113. ANTONUCCI A, Lucas AR, Costa J, Norton S, et al
     Physical activity is associated with exercise capacity among patients undergoing chemotherapy: A pilot randomized controlled trial.
     PLoS One. 2025;20:e0329774.
     PubMed         Abstract available
     
     
114. BENMUSSA C, Sanfeliu E, Martinez-Romero A, Gonzalez-Farre B, et al
     Latent representation of H&E images retains biological information in a breast cancer cohort.
     PLoS One. 2025;20:e0329221.
     PubMed         Abstract available
     
     
115. WEN M, Zeng Y, Zhang P, Yang J, et al
     Investigation of anxiety levels and associated factor analysis in breast cancer patients undergoing chemotherapy with implanted venous access ports during the stable phase of disease.
     PLoS One. 2025;20:e0332826.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

116. 
     Correction for Wang et al., Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.
     Proc Natl Acad Sci U S A. 2025;122:e2518601122.
     PubMed        
     
     

     
     Radiology

117. KO ES, Yu JH, Woo SY, Kim SW, et al
     Erratum for: Calcifications Affect Pathologic Complete Response and MRI Prediction after Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer.
     Radiology. 2025;316:e259015.
     PubMed        
     
     

     
     Radiother Oncol

118. JOSEPH K, Ademola A, Zebak J, Singh A, et al
     Adjuvant radiotherapy alone, an effective treatment option for early-stage low- risk breast cancer in women over 50: results from a population based cohort study using a Canadian provincial database.
     Radiother Oncol. 2025 Sep 29:111175. doi: 10.1016/j.radonc.2025.111175.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.